Summit Therapeutics Stock Surges
This is a news story, published by Yahoo Finance, that relates primarily to Summit news.
drug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsYahoo Finance news
For more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Summit Therapeutics. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest new drug Ivonescimab news, lung cancer antibody Ivonescimab news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
L1 lung cancer drugsThe Motley Fool
•Shares of Summit Therapeutics rocketed 123.4% this week. Here's why
66% Informative
Summit Therapeutics' new drug Ivonescimab bested Keytruda in a phase 3 clinical trial.
Wall Street analysts hiked their price targets on Summit 's stock.
Management took advantage of Wall Street's enthusiasm to raise $235 million in an equity raise announced Thursday .
It's very difficult to know whether Summit is a buy or not at this point.
VR Score
53
Informative language
50
Neutral language
25
Article tone
formal
Language
English
Language complexity
50
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
8
Source diversity
3
Affiliate links
no affiliate links